These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22534478)

  • 1. Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy.
    Zha Y; Cun Y; Zhang Q; Li Y; Tan J
    Hepatogastroenterology; 2012; 59(117):1327-32. PubMed ID: 22534478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
    Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
    Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer].
    Qu JJ; Shi YR; Hao FY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):276-80. PubMed ID: 23536352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
    Yu J; Gao J; Lu Z; Li Y; Shen L
    Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
    Gao J; Lu M; Yu JW; Li YY; Shen L
    BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
    Kelsey CR; Chino JP; Willett CG; Clough RW; Hurwitz HI; Morse MA; Bendell JC; D'Amico TA; Czito BG
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):770-6. PubMed ID: 17889266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary evaluation of adjuvant chemotherapy against stage Ib or II gastric cancer].
    Inada T; Kawakubo H; Ichikawa A; Ogata Y
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):315-20. PubMed ID: 10065094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.
    Fondevila C; Metges JP; Fuster J; Grau JJ; Palacín A; Castells A; Volant A; Pera M
    Br J Cancer; 2004 Jan; 90(1):206-15. PubMed ID: 14710231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
    Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
    Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.